GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.


Journal

Journal of neuropathology and experimental neurology
ISSN: 1554-6578
Titre abrégé: J Neuropathol Exp Neurol
Pays: England
ID NLM: 2985192R

Informations de publication

Date de publication:
01 12 2019
Historique:
pubmed: 19 10 2019
medline: 18 6 2020
entrez: 19 10 2019
Statut: ppublish

Résumé

ROS1 is a transmembrane receptor tyrosine kinase proto-oncogene that has been shown to have rearrangements with several genes in glioblastoma and other neoplasms, including intrachromosomal fusion with GOPC due to microdeletions at 6q22.1. ROS1 fusion events are important findings in these tumors, as they are potentially targetable alterations with newer tyrosine kinase inhibitors; however, whether these tumors represent a distinct entity remains unknown. In this report, we identify 3 cases of unusual pediatric glioma with GOPC-ROS1 fusion. We reviewed the clinical history, radiologic and histologic features, performed methylation analysis, whole genome copy number profiling, and next generation sequencing analysis for the detection of oncogenic mutation and fusion events to fully characterize the genetic and epigenetic alterations present in these tumors. Two of 3 tumors showed pilocytic features with focal expression of synaptophysin staining and variable high-grade histologic features; the third tumor aligned best with glioblastoma and showed no evidence of neuronal differentiation. Copy number profiling revealed chromosome 6q22 microdeletions corresponding to the GOPC-ROS1 fusion in all 3 cases and methylation profiling showed that the tumors did not cluster together as a single entity or within known methylation classes by t-Distributed Stochastic Neighbor Embedding.

Identifiants

pubmed: 31626289
pii: 5593615
doi: 10.1093/jnen/nlz093
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
GOPC protein, human 0
Golgi Matrix Proteins 0
MAS1 protein, human 0
Oncogene Proteins, Fusion 0
Proto-Oncogene Mas 0
Proto-Oncogene Proteins 0
Protein-Tyrosine Kinases EC 2.7.10.1
ROS1 protein, human EC 2.7.10.1

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1089-1099

Informations de copyright

© 2019 American Association of Neuropathologists, Inc. All rights reserved.

Auteurs

Timothy E Richardson (TE)

Department of Pathology, State University of New York, Upstate Medical University, Syracuse, New York.

Karen Tang (K)

Department of Pediatrics.

Varshini Vasudevaraja (V)

Department of Pathology, New York University Langone Health, New York, New York.

Jonathan Serrano (J)

Department of Pathology & Laboratory Medicine, Nationwide Children's Hospital and The Ohio State University.

Christopher M William (CM)

Department of Neurological Surgery, Nationwide Children's Hospital.

Kanish Mirchia (K)

Department of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital and The Ohio State University.

Christopher R Pierson (CR)

Nationwide Children's Hospital, The Institute for Genomic Medicine, Columbus, Ohio.

Jeffrey R Leonard (JR)

Department of Neurosurgery.

Mohamed S AbdelBaki (MS)

Department of Pediatrics (MAC), State University of New York, Upstate Medical University, Syracuse, New York.

Kathleen M Schieffer (KM)

Waters Center for Children's Cancer and Blood Disorders, State University of New York, Upstate Cancer Center, Syracuse, New York.

Catherine E Cottrell (CE)

Department of Pathology, State University of New York, Upstate Medical University, Syracuse, New York.

Zulma Tovar-Spinoza (Z)

Department of Pediatrics.

Melanie A Comito (MA)

Department of Pathology, New York University Langone Health, New York, New York.

Daniel R Boué (DR)

Department of Pathology & Laboratory Medicine, Nationwide Children's Hospital and The Ohio State University.

George Jour (G)

Department of Neurological Surgery, Nationwide Children's Hospital.

Matija Snuderl (M)

Department of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital and The Ohio State University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH